An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL): The Bright Study

被引：0

作者：

Flinn, Ian W. ^{[1
]}

Van der Jagt, Richard H. ^{[2
]}

Kahl, Brad S. ^{[3
]}

Wood, Peter ^{[4
]}

Hawkins, Tim E. ^{[5
]}

MacDonald, David ^{[6
,7
]}

Hertzberg, Mark ^{[8
]}

Kwan, Yiu-Lam ^{[9
]}

Simpson, David ^{[10
]}

Craig, Michael ^{[11
]}

Kolibaba, Kathryn ^{[12
]}

Issa, Samar ^{[13
]}

Munteanu, Mihaela C. ^{[14
]}

Clementi, Regina ^{[15
]}

Chen, Ling ^{[16
]}

Burke, John M. ^{[17
]}

机构：

[1] Sarah Cannon Res Inst, Nashville, TN USA

[2] Univ Ottawa, Canadian Leukemia Studies Grp, Ottawa Hosp, Ottawa, ON, Canada

[3] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[4] Princess Alexandra Hosp, Dept Hematol, Woolloongabba, Qld 4102, Australia

[5] Auckland Hosp, Auckland 1023, New Zealand

[6] QEII Hlth Sci, Hematol, Halifax, NS, Canada

[7] Capital Dist Hlth Author, Halifax, NS, Canada

[8] Westmead Hosp, Westmead, NSW, Australia

[9] Concord Repatriat Gen Hosp, Sydney, NSW 2139, Australia

[10] N Shore Hosp, Auckland, New Zealand

[11] W Virginia Univ, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA

[12] McKesson Specialty Hlth US Oncol Res, The Woodlands, TX USA

[13] Middlemore Hosp, Haematol Lymphoma Serv, Auckland 1640, New Zealand

[14] Teva Pharmaceut Ind Ltd, Clin Operat, Oncol & Immunol, Frazer, PA USA

[15] Teva Pharmaceut Ind Ltd, Amer Reg Clin Management, Global Clin Operat, Frazer, PA USA

[16] Teva Pharmaceut Ind Ltd, Biostat, Frazer, PA USA

[17] Rocky Mt Canc Ctr, Aurora, CO USA

来源：

BLOOD | 2012年 / 120卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

902

引用

页数：3

共 50 条

[31] BENDAMUSTINE PLUS RITUXIMAB VERSUS R-CHOP AS FIRST-LINE TREATMENT FOR PATIENTS WITH INDOLENT NON-HODGKIN'S LYMPHOMA: EVIDENCE FROM A MULTICENTER, RETROSPECTIVE STUDY
Mondello, P.
Steiner, N.
Willenbacher, W.
Wasle, I.
Zaja, F.
Zambello, R.
Visentin, A.
Mauro, E.
Ferrero, S.
Ghione, P.
Pitini, V.
Cuzzocrea, S.
Mian, M.
HAEMATOLOGICA, 2016, 101 : 276 - 276
[32] Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study
Mondello, Patrizia
Steiner, Normann
Willenbacher, Wolfgang
Wasle, Ines
Zaja, Francesco
Zambello, Renato
Visentin, Andrea
Mauro, Endri
Ferrero, Simone
Ghione, Paola
Pitini, Vincenzo
Cuzzocrea, Salvatore
Mian, Michael
ANNALS OF HEMATOLOGY, 2016, 95 (07) : 1107 - 1114
[33] Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study
Patrizia Mondello
Normann Steiner
Wolfgang Willenbacher
Ines Wasle
Francesco Zaja
Renato Zambello
Andrea Visentin
Endri Mauro
Simone Ferrero
Paola Ghione
Vincenzo Pitini
Salvatore Cuzzocrea
Michael Mian
Annals of Hematology, 2016, 95 : 1107 - 1114
[34] Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubucin and Rituximab (da-EPOCH-R) Vs Rituxan, Cyclophosphamide, Doxorubucin, Vincristine and Prednisone (R-CHOP) As First Line Treatment for Diffuse Large B-Cell Lymphoma (DLBCL)
Padhi, Parikshit
Chilkulwar, Abhishek
Khan, Cyrus
Patel, Monank
Lister, John
Tang, Xiaoqin
BLOOD, 2016, 128 (22)
[35] Interim results of a phase III study of bendamustine/rituximab versus R-CHOP as first-line therapy for patients with indolent non-Hodgkin lymphoma
Jagannath, Sundar
Cunningham, Sonia
CLINICAL LYMPHOMA & MYELOMA, 2008, 8 (01) : 13 - 14
[36] Polatuzumab Vedotin plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Results from the Phase III POLARIX Study
Tilly, Herve
Morschhauser, Franck
Sehn, Laurie H.
Friedberg, Jonathan W.
Trneny, Marek
Sharman, Jeff P.
Herbaux, Charles
Burke, John M.
Matasar, Matthew
Rai, Shinya
Izutsu, Koji
Mehta-Shah, Neha
Oberic, Lucie
Chauchet, Adrien
Jurczak, Wojciech
Song, Yuqin
Greil, Richard
Mykhalska, Larysa
Miguel, Juan
Burgues, Bergua
Cheung, Matthew C.
Pinto, Antonio
Shin, Ho-Jin
Hapgood, Greg
Munhoz, Eduardo
Abrisqueta, Pau
Gau, Jyh-Pyng
Hirata, Jamie
Jiang, Yanwen
Yan, Mark
Lee, Calvin
Flowers, Christopher
Salles, Gilles
Collins, Graham
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 14 - 16
[37] Post-chemotherapy cognitive impairment in patients with B-cell non-Hodgkin lymphoma: a first comprehensive approach to determine cognitive impairments after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or rituximab and bendamustine
Zimmer, Philipp
Mierau, Andreas
Bloch, Wilhelm
Strueder, Heiko K.
Huelsduenker, Thorben
Schenk, Alexander
Fiebig, Leonie
Baumann, Freek T.
Hahn, Moritz
Reinart, Nina
Hallek, Michael
Elter, Thomas
LEUKEMIA & LYMPHOMA, 2015, 56 (02) : 347 - 352
[38] Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin’s lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19)
M. Herold
A. Schulze
D. Niederwieser
A. Franke
H. J. Fricke
P. Richter
M. Freund
B. Ismer
K. Dachselt
C. Boewer
V. Schirmer
J. Weniger
R. Pasold
C. Winkelmann
C. Klinkenstein
M. Schulze
H. Arzberger
K. Bremer
S. Hahnfeld
A. Schwarzer
C. Müller
Chr. Müller
Journal of Cancer Research and Clinical Oncology, 2006, 132 : 105 - 112
[39] Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-r-chp) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (r-chop) therapy in patients with previously untreated diffuse large b-cell lymphoma (dlbcl): results from the phase iii polarix study
Dietrich, Sascha
Tilly, Herve
Morschhauser, Franck
Sehn, Laurie H.
Friedberg, Jonathan W.
Trneny, Marek
Sharman, Jeff
Herbaux, Charles
Burke, John M.
Matasar, Matthew
Rai, Shinya
Izutsu, Koji
Mehta-Shah, Neha
Oberic, Lucie
Chauchet, Adrien
Jurczak, Wojciech
Song, Yu Qin
Greil, Richard
Mykhalska, Larysa
Bergua Burgues, Juan Miguel
Cheung, Matthew C.
Pinto, Antonio
Shin, Ho-Jin
Hapgood, Greg
Munhoz, Eduardo
Salles, Gilles
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 165 - 165
[40] The Follicular Lymphoma International Prognostic Index (FLIPI) predicts treatment outcome in patients with advanced stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP)
Buske, C
Hoster, E
Dreyling, M
Hasford, J
Unterhalt, M
Hiddemann, W
BLOOD, 2005, 106 (11) : 272A - 272A

← 1 2 3 4 5 →